Microenvironments Dictating Tumor Cell Dormancy

  • Paloma Bragado
  • Maria Soledad Sosa
  • Patricia Keely
  • John Condeelis
  • Julio A. Aguirre-Ghiso


The mechanisms driving dormancy of disseminated tumor cells (DTCs) remain largely unknown. Here, we discuss experimental evidence and theoretical frameworks that support three potential scenarios contributing to tumor cell dormancy. The first scenario proposes that DTCs from invasive cancers activate stress signals in response to the dissemination process and/or a growth suppressive target organ microenvironment inducing dormancy. The second scenario asks whether therapy and/or micro-environmental stress conditions (e.g. hypoxia) acting on primary tumor cells carrying specific gene signatures prime new DTCs to enter dormancy in a matching target organ microenvironment that can also control the timing of DTC dormancy. The third and final scenario proposes that early dissemination contributes a population of DTCs that are unfit for immediate expansion and survive mostly in an arrested state well after primary tumor surgery, until genetic and/or epigenetic mechanisms activate their proliferation. We propose that DTC dormancy is ultimately a survival strategy that when targeted will eradicate dormant DTCs preventing metastasis. For these non-mutually exclusive scenarios we review experimental and clinical evidence in their support.


  1. 1.
    Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846PubMedCrossRefGoogle Scholar
  2. 2.
    Klein CA (2010) Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 21(1):42–49Google Scholar
  3. 3.
    Sang L, Coller HA, Roberts JM (2008) Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321:1095–1100PubMedCrossRefGoogle Scholar
  4. 4.
    Almog N et al (2009) Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69:836–844PubMedCrossRefGoogle Scholar
  5. 5.
    Mahnke YD, Schwendemann J, Beckhove P, Schirrmacher V (2005) Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115:325–336PubMedCrossRefGoogle Scholar
  6. 6.
    Muraoka-Cook RS et al (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64:9002–9011PubMedCrossRefGoogle Scholar
  7. 7.
    Kang Y et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549PubMedCrossRefGoogle Scholar
  8. 8.
    Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252PubMedCrossRefGoogle Scholar
  9. 9.
    Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284PubMedCrossRefGoogle Scholar
  10. 10.
    Hickson JA et al (2006) The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 66:2264–2270PubMedCrossRefGoogle Scholar
  11. 11.
    Taylor J, Hickson J, Lotan T, Yamada DS, Rinker-Schaeffer C (2008) Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer Metastasis Rev 27:67–73PubMedCrossRefGoogle Scholar
  12. 12.
    Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89–104PubMedCrossRefGoogle Scholar
  13. 13.
    Barkan D et al (2010) Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 70:5706–5716PubMedCrossRefGoogle Scholar
  14. 14.
    Ossowski L, Aguirre-Ghiso JA (2010) Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 23:41–56PubMedCrossRefGoogle Scholar
  15. 15.
    Adam AP et al (2009) Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 69:5664–5672PubMedCrossRefGoogle Scholar
  16. 16.
    Ranganathan AC, Ojha S, Kourtidis A, Conklin DS, Aguirre-Ghiso JA (2008) Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res 68:3260–3268PubMedCrossRefGoogle Scholar
  17. 17.
    Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA (2006) Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 66:1702–1711PubMedCrossRefGoogle Scholar
  18. 18.
    Ranganathan AC, Adam AP, Aguirre-Ghiso JA (2006) Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 5(7):729–735Google Scholar
  19. 19.
    Taghavi P et al (2008) In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene 27:6806–6816PubMedCrossRefGoogle Scholar
  20. 20.
    Harrison LB, Sessions RB, Ki-Hong W (2003) Head and neck cancer. A multidisciplinary approach, Wolters Kluwer-Lippincott Williams & Wilkins, Philadelphia, p 960Google Scholar
  21. 21.
    Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456PubMedCrossRefGoogle Scholar
  22. 22.
    Gath HJ, Brakenhoff RH (1999) Minimal residual disease in head and neck cancer. Cancer Metastasis Rev 18:109–126PubMedCrossRefGoogle Scholar
  23. 23.
    Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour dormancy. Apmis 116:754–770PubMedCrossRefGoogle Scholar
  24. 24.
    Klein CA (2008) The direct molecular analysis of metastatic precursor cells in breast cancer: a chance for a better understanding of metastasis and for personalised medicine. Eur J Cancer 44(18):2721–2725PubMedCrossRefGoogle Scholar
  25. 25.
    Husemann Y et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58–68PubMedCrossRefGoogle Scholar
  26. 26.
    Ossowski L, Russo H, Gartner M, Wilson EL (1987) Growth of a human carcinoma (HEp3) in nude mice: rapid and efficient metastasis. J Cell Physiol 133:288–296PubMedCrossRefGoogle Scholar
  27. 27.
    Aguirre-Ghiso JA, Ossowski L, Rosenbaum SK (2004) Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res 64:7336–7345PubMedCrossRefGoogle Scholar
  28. 28.
    Fan X et al (2002) Transient disruption of autocrine TGF-beta signaling leads to enhanced survival and proliferation potential in single primitive human hemopoietic progenitor cells. J Immunol 168:755–762PubMedGoogle Scholar
  29. 29.
    Fortunel N et al (2000) Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-beta type II receptor in a short-term in vitro assay. Stem Cells 18:102–111PubMedCrossRefGoogle Scholar
  30. 30.
    Scandura JM, Boccuni P, Massague J, Nimer SD (2004) Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci U S A 101:15231–15236PubMedCrossRefGoogle Scholar
  31. 31.
    Yamazaki S et al (2009) TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113:1250–1256PubMedCrossRefGoogle Scholar
  32. 32.
    Dumont N, Arteaga CL (2003) Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3:531–536PubMedCrossRefGoogle Scholar
  33. 33.
    Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807–821PubMedCrossRefGoogle Scholar
  34. 34.
    Hideshima T, Podar K, Chauhan D, Anderson KC (2005) Cytokines and signal transduction. Best Pract Res Clin Haematol 18:509–524PubMedCrossRefGoogle Scholar
  35. 35.
    Adorno M et al (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87–98PubMedCrossRefGoogle Scholar
  36. 36.
    Javelaud D, Alexaki VI, Mauviel A (2008) Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 21:123–132PubMedCrossRefGoogle Scholar
  37. 37.
    Hussein MR (2005) Transforming growth factor-beta and malignant melanoma: molecular mechanisms. J Cutan Pathol 32:389–395PubMedCrossRefGoogle Scholar
  38. 38.
    Hsu MY, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D (2005) Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev 24:251–263PubMedCrossRefGoogle Scholar
  39. 39.
    Reed JA et al (2001) Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 61:8074–8078PubMedGoogle Scholar
  40. 40.
    Schardt JA et al (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8:227–239PubMedCrossRefGoogle Scholar
  41. 41.
    Zapas JL et al (2003) The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg 197:403–407PubMedCrossRefGoogle Scholar
  42. 42.
    Gamel JW, George SL, Edwards MJ, Seigler HF (2002) The long-term clinical course of patients with cutaneous melanoma. Cancer 95:1286–1293PubMedCrossRefGoogle Scholar
  43. 43.
    Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T (2000) Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 107:1443–1449PubMedCrossRefGoogle Scholar
  44. 44.
    Villanueva A et al (2010) New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 16:4688–4694Google Scholar
  45. 45.
    Wang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679PubMedGoogle Scholar
  46. 46.
    Troester MA et al (2009) Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res 15:7020–7028PubMedCrossRefGoogle Scholar
  47. 47.
    Budhu A et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99–111PubMedCrossRefGoogle Scholar
  48. 48.
    Holzel D, Eckel R, Emeny RT, Engel J (2010) Distant metastases do not metastasize. Cancer Metastasis Rev 29:737–750Google Scholar
  49. 49.
    Pawitan Y et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953–R964PubMedCrossRefGoogle Scholar
  50. 50.
    Kim MY et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315–1326PubMedCrossRefGoogle Scholar
  51. 51.
    Aguirre-Ghiso JA (2010) On the theory of tumor self-seeding: implications for metastasis progression in humans. Breast Cancer Res 12:304PubMedCrossRefGoogle Scholar
  52. 52.
    McAllister SS et al (2008) Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133:994–1005PubMedCrossRefGoogle Scholar
  53. 53.
    Braun S et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRefGoogle Scholar
  54. 54.
    Braun S et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802PubMedCrossRefGoogle Scholar
  55. 55.
    Offner S et al (1999) p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci U S A 96:6942–6946PubMedCrossRefGoogle Scholar
  56. 56.
    Beausejour CM et al (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. Embo J 22:4212–4222PubMedCrossRefGoogle Scholar
  57. 57.
    Kouros-Mehr H et al (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13:141–152PubMedCrossRefGoogle Scholar
  58. 58.
    Maneechotesuwan K et al (2009) Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 6:e1000076PubMedCrossRefGoogle Scholar
  59. 59.
    Maneechotesuwan K et al (2007) Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 178:2491–2498PubMedGoogle Scholar
  60. 60.
    Wen H-C et al (2011) p38alpha Signaling induces anoikis and lumen formation during mammary morphogenesis. Sci Signal 4:ra34Google Scholar
  61. 61.
    Stott SL et al (2010) Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2:25ra23Google Scholar
  62. 62.
    Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW (2010) Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 184:702–712PubMedCrossRefGoogle Scholar
  63. 63.
    Wyckoff J et al (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029PubMedCrossRefGoogle Scholar
  64. 64.
    Qian B et al (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4:e6562PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Paloma Bragado
    • 1
  • Maria Soledad Sosa
    • 1
  • Patricia Keely
    • 2
  • John Condeelis
    • 3
  • Julio A. Aguirre-Ghiso
    • 1
    • 4
  1. 1.Division of Hematology and Oncology, Department of Medicine, Department of OtolaryngologyMount Sinai School of Medicine, Tisch Cancer Institute, Black Family Stem Cell InstituteNew YorkUSA
  2. 2.Laboratory for Cellular and Molecular Biology, Department of Cell and Regenerative Biology University of Wisconsin-Madison, R. M. Bock LaboratoriesMadisonUSA
  3. 3.Department of Anatomy and Structural BiologyGruss Lipper Biophotonics Center, Albert Einstein Cancer Center, Tumor Microenvironment and Metastasis ProgramNew YorkUSA
  4. 4.Division of Hematology and Oncology, Department of Medicine, Department of Otolaryngology, Head and Neck Cancer Research ProgramMount Sinai School of MedicineNew YorkUSA

Personalised recommendations